Sunday, September 16, 2012

Researchers Reveal Why Some Pain Drugs Become Less Effective Over Time



Newswire
Researchers at the University of Montreal’s Sainte-Justine Hospital have identified how neural cells are able to build up resistance to opioid pain drugs within hours. 

“A better understanding of these mechanisms will enable us to design drugs that avoid body resistance to these drugs and produce longer therapeutic responses, including prolonged opioid analgesia”, lead author Dr. Graciela Pineyro said.


Humans have known about the usefulness of opioids, which are often harvested from poppy plants, for centuries, but we have very little insight into how they lose their effectiveness in the hours, days and weeks following the first dose.

“Our study revealed cellular and molecular mechanisms within our bodies that enable us to develop resistance to this medication, or what scientists call drug tolerance,” she added.


The research team looked at how drug molecules would interact with molecules called “receptors” that exist in every cell in our body. 


Receptors, as the name would suggest, receive “signals” from the chemicals that they come into contact with, and the signals then cause the various cells to react in different ways. 

They sit on the cell wall, and wait for corresponding chemicals known as receptor ligands to interact with them. 

Ligands can be produced by our bodies or introduced, for example, as medication. 

“Until now, scientists have believed that ligands acted as ‘on-off’ switches for these receptors, all of them producing the same kind of effect with variations in the magnitude of the response they elicit,” Pineyro explained.

“We now know that drugs that activate the same receptor do not always produce the same kind of effects in the body, as receptors do not always recognize drugs in the same way. Receptors will configure different drugs into specific signals that will have different effects on the body.”


Once activated by a drug, receptors move from the surface of the cell to its interior, and once they have completed this ‘journey’, they can either be destroyed or return to the surface and used again through a process known as “receptor recycling.” 


By comparing two types of opioids – DPDPE and SNC-80 – the researchers found that the ligands (chemicals that enable interaction with the cell) that encouraged recycling produced less analgesic tolerance than those that didn’t. 

“We propose that the development of opioid ligands that favour recycling could be away of producing longer-acting opioid analgesics,” Pineyro said.


Pineyro is attempting to tease the “painkilling” function of opioids from the part that triggers mechanisms that enable tolerance build up. 


“My laboratory and my work are mostly structured around rational drug design, and trying to define how drugs produce their desired and non-desired effects, so as to avoid the second, Pineyro said. 

“If we can understand the chemical mechanisms by which drugs produce therapeutic and undesired side effects, we will be able to design better therapeutic agents.”




Notes:

The study “Differential association of receptor-Gβγ complexes with β-arrestin2 determines recycling bias and potential for tolerance of delta opioid receptor (DOR) agonists” was published in The Journal of Neuroscience on April 3, 2012. 


The research was funded by the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research.

Dr. Graciela Pineyro, MD, PhD is affiliated with the Departments of Psychiatry and Pharmacology at the University of Montreal and the Sainte-Justine University Hospital Center (UHC)’ Research Center. 

The University of Montreal and the Sainte-Justine UHC’s Research Centre are officially known as Université de Montréal and Centre de recherche du Centre hospitalier universitaire Sainte-Justine, respectively.




Contact details:

Dr. Graciela Pineyro is available for interview in English, French or Spanish upon appointment. 


To make an appointment, please contact William Raillant-Clark of the University of Montreal at +1-514-343-7593 or w.raillant-clark@umontreal.ca .



Researchers Reveal Why Some Pain Drugs Become Less Effective Over Time

 Source: Universite de Montreal



 

Brain Aerobics make sense considering the discovery of brain plasticity.



My hobby is to listen to lectures from various universities that are posted on-line and listening to TED Conference speakers.



 - some people listen to recorded lectures on mobile devices (my desktop is my chosen device combined with good quality sound speakers)



- how do some sound engineers make these lectures digestible...



 Begin with Guidelines: 


- four experiences:  spatial,  corporeal, temporal  and relational... are a good starting point and can be found in this ancient article:

Van Manen, M. (1997). Researching Lived Experience: Human Science for an Action"


I call this 15 year old article "ancient" because the field is dynamic and probably sound engineers are gaining knowledge at the speed of the many changes in the Internet and digital technologies.


My interest is in listening to the lectures, not in lecturing or in making YouTube vignettes of myself giving speeches.  Sound engineering is well-beyond my 2nd year level physics course or my years of studying and being involved with financial markets.  I am merely a dilettante interested in knowledge for knowledge's sake.


Scientists like Michael Merzinich suggest giving our brain a work-out now and then to stave off dementia and other mental fogginess that arrives along with the aging process.  I know this because I read books and listen to speeches like the following.




Michael Merzenich studies neuroplasticity -- the brain's powerful ability to change itself and adapt -- and ways we might make use of that plasticity to heal injured brains and enhance the skills in healthy ones.

Why you should listen to him:

One of the foremost researchers of neuroplasticity, Michael Merzenich's work has shown that the brain retains its ability to alter itself well into adulthood -- suggesting that brains with injuries or disease might be able to recover function, even later in life. He has also explored the way the senses are mapped in regions of the brain and the way sensations teach the brain to recognize new patterns. Merzenich wants to bring the powerful plasticity of the brain into practical use through technologies and methods that harness it to improve learning. He founded Scientific Learning Corporation, which markets and distributes educational software for children based on models of brain plasticity. He is co-founder and Chief Science Officer of Posit Science, which creates "brain training" software also based on his research. Merzenich is professor emeritus of neuroscience at the University of California, San Francisco.
"Merzenich is perhaps the most recognizable figure in brain plasticity and how one develops competence through experience and learning."
Dominique M. Durand   Source:  http://www.ted.com/speakers/michael_merzenich.html 

Michael Merzenich on the Web

 LINK to Speech :  http://www.ted.com/talks/michael_merzenich_on_the_elastic_brain.html

Related Speakers

Related themes

Conferences

  • TED2004

Dietary fat and Coronary Heart Disease


By David Liu, PHD



Wednesday Aug 15, 2012 (foodconsumer.org) --

A person's risk for coronary heart disease is strongly influenced by his diet.

It has been known that a plant-based diet can completely stop the progression of the disease or even reverse the disease condition in many cases.


A review article by W.C. Willett of Department of Nutrition at Harvard School of Public Health in Boston MA suggests that dietary fats actually play a major role in the risk of coronary heart disease.


For his report published in the July 2012 issue of Journal of Internal Medicine, Dr. Willett reviewed 95 studies of all sorts including experimental studies, epidemiological studies and trials. 


He has found something that may help food consumers understand the role of each major type of dietary fat in the risk of coronary heart disease.


Trans fat, commonly known as partially hydrogenated vegetable oils should be eliminated from everyone's diet, according to the author, as  

they pose clear adverse effects on the risk of coronary heart disease.


It should be noted that beef and dairy products carry naturally occuring trans fat (about 15% of total fat), which is also detrimental.


Harvard nutritionists and epidemiologists have suggested that trans fat is involved in more than 100,000 deaths from heart disease.


Intake of saturated fat should be controlled and reduced intake of this type of fat may also moderately reduce the risk of coronary heart disease if saturated fat is replaced by a combination of polyunsaturated and monounsaturated fat.


Replacement of saturated fat with certain carbohydrates may also further reduce the risk of coronary heart disease. But it should be remembered that not all carbohydrates are good. Replacing saturated fat with added sugar such as cane sugar or high fructose corn syrup may not help.


Dr. Willett says in his report "both N-6 and N-3 polyunsaturated fatty acids are essential and reduce risk of heart disease, the ratio of N-6 to N-3 is not useful and can be misleading." 

This does not mean that omega-3 fatty acids are not helpful. Many nutritionists believe a low ratio of N-6 to N-3 is desirable.


Generally speaking, Americans are believed to have too high intake of omega-6 polyunsaturated fat from vegetables, which is not good for the protection against coronary heart disease.


Two undesirable oils are corn oil and soybean oil because they contain too much N-6.


In reality, the author suggests that reducing red meat and dairy products (they likely contain naturally occurring trans fat) and increasing intakes of nuts, soy foods, fish and non-hydrogenated vegetable oils can improve the fatty acid profile and help protect against coronary heart disease.


Additionally, "a diet generous in fruits, vegetables and whole grains and low in refined starches, sugar-sweetened beverages, potatoes and salt " helps prevent coronary heart disease. 


This diet is similar to the plant-based diet Dr. T. Colin Campbell, a Cornell University nutrition professor suggests.


Dr. Dean Ornish, a professor of University of California in San Fransisco in California used a plant-based diet and a lifestyle program to treat coronary heart disease patients. 


The efficacy is up to 99% and the treatment can stop effectively progression of the disease and in many cases reverse the condition.


President Bill Clinton is now using a plant-based diet (still using some fish) as advised by Dr. Ornish, and he claims that he feels much better now than ever.



Coronary heart disease kills about 600,000 Americans each year, according to the Centers for Disease Control and Prevention.



foodconsumer.org - Dietary fat and coronary heart disease


Link: http://www.foodconsumer.org/newsite/Nutrition/Diet/dietary_fat_and_coronary_heart_disease_0815120714.html

Blogger: My Fawlty Wiring


Thursday, September 13, 2012

Albert Einstein on Giving Back


Now learn how to get smarter

A hundred times every day I remind myself that my inner and outer life are based on the labors of other men, living and dead, and that I must exert myself in order to give in the same measure as I have received and am still receiving...




GET A LIFE NOW


Symptoms of Living




Tuesday, September 4, 2012

Video: Brown fat measured by thermal imaging - Telegraph












Brown fat measured by thermal imaging

Heat-seeking cameras could be used to measure people's "good fat" and determine which foods they ought to be avoiding, scientists claim. 

Brown fat is good for our bodies because it burns calories by producing large amounts of heat, which could help us avoid storing surplus energy as white fat around our waistlines.
Although it had long been known that newborn babies used brown fat to keep them warm, scientists only recently discovered that we retain small deposits of it even in adulthood.
Now researchers from Nottingham University suggest that by measuring someone's levels of brown fat, and most importantly how hot it is, they could determine which foods will help them lose or gain weight.
In a new study in the Journal of Pediatrics, Prof Michael Symonds and Dr Helen Budge demonstrated that thermal imaging cameras can be used to accurately trace people's brown fat deposits.
Because brown fat produces 300 times more heat than any other tissue type, heat-sensitive technology cannot only identify it but measure how active it is, or how much heat it is producing.
The thermal imaging technique avoids the potentially harmful radiation which has been used in previous studies to measure brown fat in adults, and which has prevented scientists accurately measuring brown fat in children for safety reasons.

By using the new technique on children as well as adults, the researchers demonstrated that children have larger stores of brown fat and produce heat much more rapidly than adults.
Dr Budge said: "Brown fat does appear to be present in higher amounts in larger people than in people of lower body weight, but we think the key difference is in how active it is from person to person.

"The reason this is exciting is that if you "switch on" brown fat and it uses up energy, then potentially that is one way of controlling body weight."

Further studies of how brown fat responds to different food groups could enable food manufacturers to include a new category of health advice on food packaging, the researchers added.

Prof Symonds said: “Potentially we could add a thermogenic index to food labels to show whether that product would increase or decrease heat production within brown fat. In other words whether it would speed up or slow down the amount of calories we burn.”




Link:  http://www.telegraph.co.uk/health/healthnews/9409635/Brown-fat-measured-by-thermal-imaging.html

Video: Brown fat measured by thermal imaging - Telegraph




 

Monday, June 25, 2012

Robbie Burns: To A Mouse

A sculpture of a mouse in the garden of the Robert Burns Birthplace Museum, Alloway
 
 
TO A MOUSE
ON TURNING HER UP IN HER NEST WITH THE PLOUGH, NOVEMBER, 1785
by: Robert Burns (1759-1796)
      I
       
      EE, sleekit, cowrin, tim'rous beastie,
      Oh, what a panic's in thy breastie!
      Thou need na start awa sae hasty,
      Wi' bickering brattle!
      I was be laith to rin an' chase thee,
      Wi' murd'ring pattle!
       
      II
       
      I'm truly sorry man's dominion
      Has broken Nature's social union,
      An' justifies that ill opinion
      Which makes thee startle
      At me, thy poor, earth-born companion
      An' fellow-mortal!
       
      III
       
      I doubt na, whyles, but thou may thieve;
      What then? poor beastie, thou maun live!
      A daimen-icker in a thrave
      'S a sma' request;
      I'll get a blessin wi' the lave,
      And never miss't!
       
      IV
       
      Thy wee-bit housie, too, in ruin!
      Its silly wa's the win's are strewin!
      An' naething, now, to big a new ane,
      O' foggage green!
      An' bleak December's winds ensuin,
      Baith snell an' keen!
       
      V
       
      Thou saw the fields laid bare an' waste,
      An' weary winter comin fast,
      An' cozie here, beneath the blast,
      Thou thought to dwell,
      Till crash! the cruel coulter past
      Out thro' thy cell.
       
      VI
       
      That wee bit heap o' leaves an stibble,
      Has cost thee mony a weary nibble!
      Now thou's turn'd out, for a' thy trouble,
      But house or hald,
      To thole the winter's sleety dribble,
      An' cranreuch cauld!
       
      VII
       
      But, Mousie, thou art no thy lane,
      In proving foresight may be vain:
      The best-laid schemes o' mice an' men
      Gang aft a-gley,
      An' lea'e us nought but grief an' pain,
      For promis'd joy!
       
      VIII
       
      Still thou art blest, compared wi' me!
      The present only toucheth thee:
      But och! I backward cast my e'e,
      On prospects drear!
      An' forward, tho' I cannot see,
      I guess an' fear!
"To a Mouse" is reprinted from English Poems. Ed. Edward Chauncey Baldwin & Harry G. Paul. New York: American Book Company, 1908.

 Source:
 http://www.poetry-archive.com/b/to_a_mouse.html



 Portrait of Robert Burns 
 Robert Burns by Alexander Nasmyth
(By permission of the National Galleries of Scotland) 


Friday, May 18, 2012

Diabesity: Balance Your Hormones

06 Balance Your Hormones YouTube - YouTube




About Dr Mark Hyman

MARK HYMAN, MD is dedicated to identifying and addressing the root causes of chronic illness through a groundbreaking whole-systems medicine approach called Functional Medicine. He is a family physician, a five-time New York Times bestselling author, and an international leader in his field. Through his private practice, education efforts, writing, research, and advocacy, he empowers others to stop managing symptoms and start treating the underlying causes of illness, thereby tackling our chronic-disease epidemic. More about Dr. Hyman or on Functional Medicine.




There is an obesity epidemic in the United States and parts of the world — especially among children. Now, we are learning about obesity's intimate relationship with diabetes.
By Mary Best
When Francine Kaufman, M.D., talks about diabetes and obesity, it's easy to hear her passionate commitment to educate parents and children about this growing problem. "I am concerned about our children," says Dr. Kaufman, who is the incoming chairperson for the National Diabetes Education Program (NDEP). "I've devoted my career to diabetes in children. Particularly now, when we are at the point of an epidemic of childhood obesity and the development of type 2 diabetes in children, I have realized that to make a difference, we have to change the environment for children."
She has seen firsthand the effect of a poor diet on the body. Dr. Kaufman treats thousands of children who suffer from obesity and the diseases associated with it. She is a professor of pediatric endocrinology at the Keck School of Medicine of the University of Southern California. Dr. Kaufman is also director of the Center for Diabetes, Endocrinology, and Metabolism at Children's Hospital in Los Angeles.

To Find Out More

At www.medlineplus.gov, type "diabetes" into the Search box. There is also more information at www.niddk.nih.gov.

The Cover of Fall 2006 Medlineplus Magazine For more information on teens and diabetes, visit www.medlineplus.gov to read about juvenile diabetes as featured in the Fall 2006 issue of MedlinePlus magazine.
Nearly 21 million Americans suffered from diabetes in 2005, according to the National Institutes of Health (NIH). A national survey calculated the obesity rate for children at 17.1 percent in that same year. Dr. Kaufman predicts that by the year 2020 the number of people around the world with diabetes will soar to more than 300 million.
In her book Diabesity: The Obesity-Diabetes Epidemic That Threatens America—And What We Must Do to Stop It, Dr. Kaufman explains the roots of diabesity quite simply: "Our ancient genes and our modern environment have collided." Our bodies store excess calories as fat. In ancient times calories were hard to come by. Today, fast food and junk food are everywhere. Coupled with our increasingly inactive lifestyle, the result is obesity.
"Diabetes is everywhere around the world," says Dr. Kaufman, "and it touches people, whether they are the person with diabetes or the person caring for someone with diabetes. It has a global reach and a global impact. We need to come together as a global society to find a way to combat diabetes."

Short Cut to Abs Six Pack

Check out the body on the Chinese Scientist!!!!  This is altogether too FUNNY!!!

More truth in advertizing









http://dinersjournal.blogs.nytimes.com/2012/05/17/what-were-reading-438/?src=twr&gwh=360C0A17EC0625FECB8789028BF54F34

HDL ‘Good Cholesterol’ Found Not to Cut Heart Risk - NYTimes.com

HDL ‘Good Cholesterol’ Found Not to Cut Heart Risk - NYTimes.com


"I'd say the HDL hypothesis is on the ropes right now."
DR. JAMES A. DE LEMOS, a professor at the University of Texas Southwestern Medical Center, on findings that raising HDL cholesterol levels may not affect heart disease risk. 



May 16, 2012

Doubt Cast on the ‘Good’ in ‘Good Cholesterol’
By GINA KOLATA


The name alone sounds so encouraging: HDL, the “good cholesterol.” The more of it in your blood, the lower your risk of heart disease. So bringing up HDL levels has got to be good for health.

Or so the theory went.

Now, a new study that makes use of powerful databases of genetic information has found that raising HDL levels may not make any difference to heart disease risk. People who inherit genes that give them naturally higher HDL levels throughout life have no less heart disease than those who inherit genes that give them slightly lower levels. If HDL were protective, those with genes causing higher levels should have had less heart disease.

Researchers not associated with the study, published online Wednesday in The Lancet, found the results compelling and disturbing. Companies are actively developing and testing drugs that raise HDL, although three recent studies of such treatments have failed. And patients with low HDL levels are often told to try to raise them by exercising or dieting or even by taking niacin, which raised HDL but failed to lower heart disease risk in a recent clinical trial.

“I’d say the HDL hypothesis is on the ropes right now,” said Dr. James A. de Lemos, a professor at the University of Texas Southwestern Medical Center, who was not involved in the study.

Dr. Michael Lauer, director of the division of cardiovascular sciences at the National Heart, Lung and Blood Institute, agreed.

“The current study tells us that when it comes to HDL we should seriously consider going back to the drawing board, in this case meaning back to the laboratory,” said Dr. Lauer, who also was not connected to the research. “We need to encourage basic laboratory scientists to figure out where HDL fits in the puzzle — just what exactly is it a marker for.”

But Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, who is helping conduct studies of HDL-raising drugs, said he remained hopeful. HDL is complex, he said, and it is possible that some types of HDL molecules might in fact protect against heart disease.

“I am an optimist,” Dr. Nissen said.

The study’s authors emphasize that they are not questioning the well-documented finding that higher HDL levels are associated with lower heart disease risk. But the relationship may not be causative. Many assumed it was because the association was so strong and consistent. Researchers also had a hypothesis to explain how HDL might work. From studies with mice and with cells grown in the laboratory, they proposed that HDL ferried cholesterol out of arteries where it did not belong.

Now it seems that instead of directly reducing heart disease risk, high HDL levels may be a sign that something else is going on that makes heart disease less likely. To investigate the relationship between HDL and cardiovascular risk, the researchers, led by Dr. Sekar Kathiresan, director of preventive cardiology at Massachusetts General Hospital and a geneticist at the Broad Institute of M.I.T. and Harvard, used a method known as Mendelian randomization. It is a study design that has recently become feasible with the advent of quick and lower-cost genetic analyses.

The idea is that people inherit any of a wide variety of genetic variations that determine how much HDL they produce. The result is that people are naturally and randomly assigned by these variations in their inherited genes to make more, or less, HDL, throughout their lives. If HDL reduces the risk of heart disease, then those who make more should be at lower risk.

For purposes of comparison, the researchers also examined inherited variations in 13 genes that determine levels of LDL, the so-called bad cholesterol. It is well known and widely accepted that lowering LDL levels by any means — diet and exercise, statin drugs — reduces risk. Clinical trials with statins established with certainty that reducing LDL levels is protective. So, the researchers asked, did people who inherited gene variations that affected their LDL levels, have correspondingly higher or lower heart disease risk?

The study found, as expected, that gene variations that raise LDL increase risk and those that lower LDL decrease risk. The gene effects often were tiny, altering LDL levels by only a few percent. But the data, involving tens of thousands of people, clearly showed effects on risk.

“That speaks to how powerful LDL is,” Dr. Kathiresan said.

But the HDL story was very different. First the investigators looked at variations in a well-known gene, endothelial lipase, that affects only HDL. About 2.6 percent of the population has a variation in that gene that raises their HDL levels by about 6 points. The investigators looked at 116,000 people, asking if they had the variant and if those who carried the HDL-raising variant had lower risk for heart disease.

“We found absolutely no association between the HDL-boosting variant and risk for heart disease,” Dr. Kathiresan said. “That was very surprising to us.”

Then they looked at a group of 14 gene variants that also affect HDL levels, asking if there was a relationship between these variants and risk for heart disease. The data included genetic data on 53,500 people. Once again, there was no association between having the variants that increased HDL and risk of heart disease.

Dr. Lauer explains what that means with an analogy.

“One might think of a highway accident that causes a massive traffic jam,” he said. “Stewing in the jam many miles away, I might be tempted to strike the sign that says ‘accident ahead,’ but that won’t do any good. The ‘accident-ahead’ sign is not the cause of the traffic jam — the accident is. Analogously, targeting HDL won’t help if it’s merely a sign.”

Dr. Kathiresan said there were many things HDL might indicate. “The number of factors that track with low HDL is a mile long,” he said. “Obesity, being sedentary, smoking, insulin resistance, having small LDL particles, having increased cholesterol in remnant particles, and having increased amounts of coagulation factors in the blood,” he said. “Our hypothesis is that much of the association may be due to these other factors.”

“I often see patients in the clinic with low HDL levels who ask how they can raise it,” Dr. Kathiresan said. “I tell them, ‘It means you are at increased risk, but I don’t know if raising it will affect your risk.’ ”

That often does not go over well, he added. The notion that HDL is protective is so entrenched that the study’s conclusions may prove hard to accept, he and other researchers said.

“When people see numbers in the abnormal range they want to do something about it,” Dr. Kathiresan said. “It is very hard to get across the concept that the safest thing might be to leave people alone.”



Because of an editing error, a correction with an earlier version of this article was appended mistakenly, and described niacin incorrectly. While niacin is a vitamin, as the correction noted, it is considered a drug when given at pharmaceutical doses, as in a recent trial in which it was shown to raise HDL without lowering heart disease risk.

Wednesday, May 9, 2012

Researchers Reveal Why Some Pain Drugs Become Less Effective Over Time



Researchers Reveal Why Some Pain Drugs Become Less Effective Over Time


 Source: Universite de Montreal


Newswise — Researchers at the University of Montreal’s Sainte-Justine Hospital have identified how neural cells are able to build up resistance to opioid pain drugs within hours. “A better understanding of these mechanisms will enable us to design drugs that avoid body resistance to these drugs and produce longer therapeutic responses, including prolonged opioid analgesia”, lead author Dr. Graciela Pineyro said.


Humans have known about the usefulness of opioids, which are often harvested from poppy plants, for centuries, but we have very little insight into how they lose their effectiveness in the hours, days and weeks following the first dose. “Our study revealed cellular and molecular mechanisms within our bodies that enable us to develop resistance to this medication, or what scientists call drug tolerance,” she added.


The research team looked at how drug molecules would interact with molecules called “receptors” that exist in every cell in our body. Receptors, as the name would suggest, receive “signals” from the chemicals that they come into contact with, and the signals then cause the various cells to react in different ways. They sit on the cell wall, and wait for corresponding chemicals known as receptor ligands to interact with them. Ligands can be produced by our bodies or introduced, for example, as medication. “Until now, scientists have believed that ligands acted as ‘on-off’ switches for these receptors, all of them producing the same kind of effect with variations in the magnitude of the response they elicit,” Pineyro explained. “We now know that drugs that activate the same receptor do not always produce the same kind of effects in the body, as receptors do not always recognize drugs in the same way. Receptors will configure different drugs into specific signals that will have different effects on the body.”


Once activated by a drug, receptors move from the surface of the cell to its interior, and once they have completed this ‘journey’, they can either be destroyed or return to the surface and used again through a process known as “receptor recycling.” By comparing two types of opioids – DPDPE and SNC-80 – the researchers found that the ligands (chemicals that enable interaction with the cell) that encouraged recycling produced less analgesic tolerance than those that didn’t. “We propose that the development of opioid ligands that favour recycling could be away of producing longer-acting opioid analgesics,” Pineyro said.


Pineyro is attempting to tease the “painkilling” function of opioids from the part that triggers mechanisms that enable tolerance build up. “My laboratory and my work are mostly structured around rational drug design, and trying to define how drugs produce their desired and non-desired effects, so as to avoid the second, Pineyro said. “If we can understand the chemical mechanisms by which drugs produce therapeutic and undesired side effects, we will be able to design better therapeutic agents.”




Notes:


The study “Differential association of receptor-Gβγ complexes with β-arrestin2 determines recycling bias and potential for tolerance of delta opioid receptor (DOR) agonists” was published in The Journal of Neuroscience on April 3, 2012. The research was funded by the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research. Dr. Graciela Pineyro, MD, PhD is affiliated with the Departments of Psychiatry and Pharmacology at the University of Montreal and the Sainte-Justine University Hospital Center (UHC)’ Research Center. The University of Montreal and the Sainte-Justine UHC’s Research Centre are officially known as Université de Montréal and Centre de recherche du Centre hospitalier universitaire Sainte-Justine, respectively.




Contact details:

Dr. Graciela Pineyro is available for interview in English, French or Spanish upon appointment. To make an appointment, please contact William Raillant-Clark of the University of Montreal at +1-514-343-7593 or w.raillant-clark@umontreal.ca .